Coronado Biosciences, Inc. (CNDO)

[Value_Investor]

Up 11.6% so far! CNDO hit $1.54! 23.2% big bounce from the bottom price or all time low $1.25...

[GMONEY4]

$1.52. Up 10% Nice....

[GMONEY4]

Bump.

[Value_Investor]

What is the main points, MIR? TIA!

[MissionIR]

CNDO Video Chart 11/20/2013

http://www.missionir.com/videos.html

[Value_Investor]

Huge shorting position (SP) covering now: 6.11M shares were shorted as of 10/15/2013. Then the shorting position was reduced to 3.64M shares on 10/31/2013 due to shorts covering 2.47M shares within just 16 days!

[Value_Investor]

Yes, Up 8.5% so far! $1.5 should be hit today or tomorrow...

[GMONEY4]

Nice bump so far...heavy volume.

[Value_Investor]

Finally it is up 2.36% today! LOL, $2.46/share BV vs at near 50% of the BV price ($1.3/share) now!

[Value_Investor]

A big institution recently bought 402,700 shares CNDO at over $7.01 per share price:

http://www.nasdaq.com/article/sac-capital-advisors-lp-3q-13f-largest-purchases-20131115-00381

[GMONEY4]

Looks like we're gonna test a new low today...

[bullrider2]

I'm going to wait until it gets to a buck than I'll think about buying. This could go to a penny stock very easy with testing trails being shut down or cancel.

GLTA.

[Value_Investor]

Added the cheap shares at $1.4 ~ $1.41 today!

[z_deville]

added 14.2k @ 1.39

[GMONEY4]

Nice buys coming through here at the bottom. Gaining some support @ $1.38.

[Value_Investor]

Huge shorting squeezing will kick in this week which will lead to those greedy shorter's huge losses if they don't cover ASAP...

[High Roller]

You da man! I concur :)

[Value_Investor]

The actual value for CNDO is $3 per share at least based on the current cash value, book value, and the various patents etc. IP assets...

[Value_Investor]

The cash value is $2.99 per share and the book value is $2.46 per share based on the current 10-Q released on 11/01/2013 (see the link below).

http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001193125-13-423193.txt&FilePath=\2013\11\01\&CoName=CORONADO+BIOSCIENCES+INC&FormType=10-Q&RcvdDate=11%2F1%2F2013&pdf=

The float is 27.15M shares and the OS is 35.61M shares.

Huge shorting position (SP): 6.11M shares shorted as of 10/15/2013 alone. The current shorting position could be around 7M shares now based on the same percentage of SP/OS...

The insider ownership is 20.49% and the institution ownership is 42.6%.

[Value_Investor]

$1.44 just hit!

[GMONEY4]

Bump. Looking better today. Ask looks pretty thin..

[Value_Investor]

Unfortunately the shorting MM's manipulations to crashed down $1.3201...

[Value_Investor]

Another new high $1.37 hit! More new highs very soon...

[MakinItWork]

Well I'm ready. Hopefully it takes off soon.

[Value_Investor]

Up 3% so far! Easy double from the bottom price based on the BV!

[dubbya]

Wait for just ONE proof of concept trial validation for ONE indication before throwing money at this one.

[MakinItWork]

I know you keep saying book value and hope you are right about this one. It well be a good payday for us all if it happens soon.

[Value_Investor]

It is really ridiculous low to see CNDO with $2.68 BV vs at $1.27 PPS! Easy double from the bottom within a few weeks...

[GMONEY4]

Nice. I think it's finally time to add. $1.64 the other day isn't looking to well. Double down.

[Value_Investor]

$1.35 now...

[GMONEY4]

Yep. Look's like some relief. Finally...

[Value_Investor]

Bounced to $1.33 now!

[MakinItWork]

Wish I would have waited too

[GMONEY4]

lol. I thought 1.3201..i'll check back tomorrow. No end in site today.

[Value_Investor]

It seems bottomed out at $1.27!

[dubbya]

Imagine how many shares you will be able to buy when it goes to a buck! Back up the truck, right?

[MakinItWork]

I added some too. Averaged out @ 1.62. Doesn't mean I wouldn't like it to run north already though.

[Value_Investor]

Yes. I view today's sell-off as an huge buying opportunity! Great day for me to steal those dirt cheap bottom shares!

[GMONEY4]

whew,glad i held back. I'll wait til eod or tomorrow.

[MakinItWork]

When is this going to end?

[GMONEY4]

ARCX moved his 50k block down from $1.49 to $1.47 and it filled.

[MakinItWork]

They are still involved in enough other positive things that this one negative shouldn't cause too much trouble, right? It seems that with everything else that this company will still keep producing.

[Value_Investor]

I'm busy to add those cheap shares today as I expected yesterday...

[GMONEY4]

Finally some volume though. I like it. Might try some more around $1.45 - $1.50.

[surf1944]

6:35AM Coronado Biosciences announces Independent Data Monitoring Committee recommendation to discontinue Falk Phase 2 trial of TSO in Crohn's disease (CNDO) 1.63 : Co announced that it has been informed by Dr. Falk Pharma GmbH, its development partner, that an Independent Data Monitoring Committee has conducted a second interim analysis of clinical data from ~ 240 patients who have completed 12 weeks of treatment in Falk's Phase 2 clinical trial in Europe evaluating Trichuris suis ova in Crohn's disease. The committee recommended that the trial be stopped due to lack of efficacy and noted no safety concerns. Falk has advised Coronado that it is adopting the committee's recommendations and discontinuing the study.

"We are not surprised by these results, given the disappointing data from our TRUST-I study. We believe TSO has therapeutic potential in other diseases and will continue to work diligently to advance its development for the treatment of autoimmune diseases and to develop CNDO-109 for the treatment of cancer."

[surf1944]

6:35AM Coronado Biosciences announces Independent Data Monitoring Committee recommendation to discontinue Falk Phase 2 trial of TSO in Crohn's disease (CNDO) 1.63 : Co announced that it has been informed by Dr. Falk Pharma GmbH, its development partner, that an Independent Data Monitoring Committee has conducted a second interim analysis of clinical data from ~ 240 patients who have completed 12 weeks of treatment in Falk's Phase 2 clinical trial in Europe evaluating Trichuris suis ova in Crohn's disease. The committee recommended that the trial be stopped due to lack of efficacy and noted no safety concerns. Falk has advised Coronado that it is adopting the committee's recommendations and discontinuing the study.

"We are not surprised by these results, given the disappointing data from our TRUST-I study. We believe TSO has therapeutic potential in other diseases and will continue to work diligently to advance its development for the treatment of autoimmune diseases and to develop CNDO-109 for the treatment of cancer."

[MakinItWork]

I saw that earlier, but it's still a viable company from what I can tell. I don't think it warrants 1.45

[GMONEY4]

$1.44 x $1.45. I would guess this news that was put out earlier this morning.

Coronado Biosciences Announces Independent Data Monitoring Committee Recommendation to Discontinue Falk Phase 2 Trial of TSO in Crohn's Disease.

6:30a ET November 7, 2013 (GlobeNewswire)
Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced that it has been informed by Dr. Falk Pharma GmbH (Falk), its development partner, that an Independent Data Monitoring Committee (IDMC) has conducted a second interim analysis of clinical data from approximately 240 patients who have completed 12 weeks of treatment in Falk's Phase 2 clinical trial in Europe evaluating Trichuris suis ova (TSO) in Crohn's disease. The committee recommended that the trial be stopped due to lack of efficacy and noted no safety concerns. Falk has advised Coronado that it is adopting the committee's recommendations and discontinuing the study.

"We are not surprised by these results, given the disappointing data from our TRUST-I study," said Dr. Harlan F. Weisman, Coronado's Chairman and CEO. "We believe TSO has therapeutic potential in other diseases and will continue to work diligently to advance its development for the treatment of autoimmune diseases and to develop CNDO-109 for the treatment of cancer."

The Falk trial, also known as the TRUST-II study, is a double-blind, randomized, placebo-controlled, multi-center Phase 2 study to evaluate the efficacy and safety of three different dosages of oral TSO in patients with active Crohn's disease. The purpose of the interim analysis was to verify the assumptions of the sample size calculation or to recalculate sample size based on the effect size estimations of the interim analysis and determine whether to discontinue the study due to futility.

About Coronado Biosciences

Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The company's two principal pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML), multiple myeloma and solid tumors. For more information, please visit www.coronadobiosciences.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks relating to the results of research and development activities; our ability to attract, integrate and retain key personnel; uncertainties relating to preclinical and clinical testing; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; our dependence on third party suppliers; and competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.


CONTACT: Lucy Lu, MD, Executive Vice President &
Chief Financial Officer
Coronado Biosciences, Inc.
781-652-4525; [e-mail]

http://media.globenewswire.com/cache/18300/small/13938.jpg

http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwNTY3NjkjMTgzMDA=

[MakinItWork]

Is there something I'm missing? What's going on here this morning?

[GMONEY4]

PM - $1.51..